Key facts
- This page summarizes Amit Sachdev's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Feb 2025, 16:14.
Amit Sachdev - 12 Feb 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- EVP Chief Patient & Ext Af Off
- Issuer ticker
- VRTX
- Reported as of
- 12 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2025, 16:14:37 UTC
- Prior SEC filing
- 12 Feb 2025
- Next SEC filing
- 19 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amit Sachdev filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 14 Feb 2025.
Change
- Previous filing in this sequence was filed on 12 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,211
- Change %
- +8.8%
- Price
- $0.000000
- Shares after
- 76,802
- Date
- 12 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 882
- Date
- 12 Feb 2025
- Ownership
- 401(k)
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Restricted stock unit award that vests in installments beginning on 02/24/2026.